Atwood & Palmer’s Galectin Therapeutics GALT Stock Holding History

Atwood & Palmer’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$38.8K	Hold	10,000	–	–	﹤0.01%	285
2026 Q2	$46.4K	Hold	10,000	–	–	﹤0.01%	254
2026 Q1	$27.9K	Hold	10,000	–	–	﹤0.01%	297
2025 Q4	$41.6K	Hold	10,000	–	–	﹤0.01%	251
2025 Q3	$42.4K	Buy	+10,000	New	+$37.6K	﹤0.01%	257

Other funds holding GALT

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Atwood & Palmer's GALT Position: Q3 2026 in Review

Atwood & Palmer held its Galectin Therapeutics (GALT) position steady in Q3 2026 at 10,000 shares worth $38.8K. The position accounts for ﹤0.01% of the portfolio, ranked #285.

Atwood & Palmer first reported a position in GALT in Q3 2025 and has held it in 5 quarters since. The position peaked at $46.4K in Q2 2026. 4 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

Atwood & Palmer held 10,000 shares of Galectin Therapeutics worth $38.8K as of Q3 2026.
Atwood & Palmer left its Galectin Therapeutics share count unchanged in Q3 2026.
Galectin Therapeutics made up ﹤0.01% of Atwood & Palmer's portfolio in Q3 2026, its #285 holding.
Atwood & Palmer first reported a position in Galectin Therapeutics in Q3 2025 and has held it in 5 quarters since.
Atwood & Palmer's Galectin Therapeutics position peaked at $46.4K in Q2 2026.
4 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on Atwood & Palmer's 13F filing for Q3 2026, filed 8 Oct 2026.